Dr. Yu Discusses Optimal Testosterone Suppression

Video

In Partnership With:

Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, discusses an analysis of optimal testosterone suppression on medical ADT.

Evan Y. Yu, MD, associate professor, Department of Medicine, Division of Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, discusses an analysis of optimal testosterone suppression on medical ADT.

There is more and more data to show that lower testosterone levels are optimal. It is currently known that LHRH agonists work well and produce similar clinical outcomes to orchiectomy, but testosterone is not lowered as well and testosterone escapes can occur.

Researchers conducted this analysis to determine the effect on testosterone and free testosterone in patients that underwent orchiectomy. Yu says this is a descriptive study meant to define what testosterone/free testosterone levels would be in a patient who had optimal androgen deprivation therapy (which would be orchiectomy).

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine